The Journal of Neuroscience, December 17, 2008, 28(51):13805-13814; doi:10.1523/JNEUROSCI.4218-08.2008
Previous Article | Next Article 
Neurobiology of Disease
Amyloid Pathology Is Associated with Progressive Monoaminergic Neurodegeneration in a Transgenic Mouse Model of Alzheimer's Disease
Ying Liu,1
Mi-Jeong Yoo,1
Alena Savonenko,1
Wanda Stirling,1
Donald L. Price,1,2,3
David R. Borchelt,1,3
Laura Mamounas,1
W. Ernest Lyons,1
Mary E. Blue,2,3,4 and
Michael K. Lee1
Departments of 1Pathology, 2Neurology, and 3Neuroscience, Johns Hopkins University, Baltimore, Maryland 21205, and 4Kennedy Krieger Research Institute, Baltimore, Maryland 21205
Correspondence should be addressed to Dr. Michael K. Lee, Department of Pathology/Neuropathology, Johns Hopkins University School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205. Email: mklee{at}jhmi.edu
β-Amyloid (Aβ) pathology is an essential pathogenic component in Alzheimer's disease (AD). However, the significance of Aβ pathology, including Aβ deposits/oligomers and glial reactions, to neurodegeneration is unclear. In particular, despite the Aβ neurotoxicity indicated by in vitro studies, mouse models with significant Aβ deposition lack robust and progressive loss of forebrain neurons. Such results have fueled the view that Aβ pathology is insufficient for neurodegeneration in vivo. In this study, because monoaminergic (MAergic) neurons show degenerative changes at early stages of AD, we examined whether the APPswe/PS1
E9 mouse model recapitulates progressive MAergic neurodegeneration occurring in AD cases. We show that the progression forebrain Aβ deposition in the APPswe/PS1
E9 model is associated with progressive losses of the forebrain MAergic afferents. Significantly, axonal degeneration is associated with significant atrophy of cell bodies and eventually leads to robust loss (
50%) of subcortical MAergic neurons. Degeneration of these neurons occurs without obvious local Aβ or tau pathology at the subcortical sites and precedes the onset of anxiety-associated behavior in the mice. Our results show that a transgenic mouse model of Aβ pathology develops progressive MAergic neurodegeneration occurring in AD cases.
Key words: Aβ-peptide; axon; serotonergic; noradrenergic; neuron death; BDNF; atrophy
Received Sept. 4, 2008;
revised Oct. 7, 2008;
accepted Nov. 3, 2008.
Correspondence should be addressed to Dr. Michael K. Lee, Department of Pathology/Neuropathology, Johns Hopkins University School of Medicine, 720 Rutland Avenue, 558 Ross Building, Baltimore, MD 21205. Email: mklee{at}jhmi.edu
This article has been cited by other articles:

|
 |

|
 |
 
F. K. Wiseman
Cognitive Enhancement Therapy for a Model of Down Syndrome
Science Translational Medicine,
November 18, 2009;
1(7):
7ps9 - 7ps9.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Salehi, M. Faizi, D. Colas, J. Valletta, J. Laguna, R. Takimoto-Kimura, A. Kleschevnikov, S. L. Wagner, P. Aisen, M. Shamloo, et al.
Restoration of Norepinephrine-Modulated Contextual Memory in a Mouse Model of Down Syndrome
Science Translational Medicine,
November 18, 2009;
1(7):
7ra17 - 7ra17.
[Abstract]
[Full Text]
[PDF]
|
 |
|